Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genus plc ( (GB:GNS) ) has provided an announcement.
Genus plc announced that as of July 31, 2025, its issued share capital consists of 66,037,454 ordinary shares with voting rights, with no shares held in treasury. This update is significant for shareholders as it affects the calculation of their interests under the FCA’s Disclosure Guidance and Transparency Rules, potentially impacting their reporting obligations.
The most recent analyst rating on (GB:GNS) stock is a Buy with a £2940.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc scores a 68, driven primarily by successful strategic initiatives and positive corporate events, including FDA approval for a key product. While technical analysis indicates strong momentum, caution is advised due to overbought signals. Financial performance and valuation reveal areas of concern, particularly in profitability and liquidity, warranting careful monitoring.
To see Spark’s full report on GB:GNS stock, click here.
More about Genus plc
Genus plc operates in the biotechnology industry, focusing on animal genetics. The company provides advanced breeding services and products to improve livestock quality and productivity, catering to agricultural markets worldwide.
Average Trading Volume: 169,718
Technical Sentiment Signal: Buy
Current Market Cap: £1.64B
Learn more about GNS stock on TipRanks’ Stock Analysis page.